Search alternatives:
ms decrease » _ decrease (Expand Search), mean decrease (Expand Search), use decreased (Expand Search)
ns decrease » _ decrease (Expand Search), we decrease (Expand Search), use decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
ms decrease » _ decrease (Expand Search), mean decrease (Expand Search), use decreased (Expand Search)
ns decrease » _ decrease (Expand Search), we decrease (Expand Search), use decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
41
-
42
-
43
Data-Driven Tool for Cross-Run Ion Selection and Peak-Picking in Quantitative Proteomics with Data-Independent Acquisition LC–MS/MS
Published 2023“…Proteomics provides molecular bases of biology and disease, and liquid chromatography–tandem mass spectrometry (LC–MS/MS) is a platform widely used for bottom-up proteomics. …”
-
44
-
45
-
46
Downregulation of TRIM37 expression exacerbates pathological damage in the MS model.
Published 2025“…Scale bar = 50 μm. (h) qRT-PCR (n = 6) and <b>(i, j)</b> Western blot (n = 3) both showed a significant decrease in the <i>TRIM37</i> mRNA and protein levels in the LPC-induced MS model compared to the control group. * <i><i>P</i></i> < 0.05, ** <i><i>P</i></i> < 0.01, *** <i><i>P</i></i> < 0.001, **** <i><i>P</i></i> < 0.0001, ns = not significant.…”
-
47
ku0063794 but not rapamycin decreased the TRPC6 mRNA levels in podocytes.
Published 2014“…<p>(A) ku0063794 (2 µmol/l) or rapamycin (50 nmol/l) was applied to evaluate the effects of mTORC1 and mTORC2 on TRPC6 in podocytes. …”
-
48
-
49
-
50
-
51
Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.
Published 2016“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”
-
52
-
53
-
54
Backbone RMSD of mutant D314N throughout a 100ns MD simulation.
Published 2016“…<p>To confirm that mutant D314N stayed stable with an RMSD of 0.6nm, we carried a 100ns MD simulation. The mutant seemed to stabilize at 12ns with an RMSD of 0.5nm, but an increase is noticeable at 40ns, when the backbone RMSD achieves 0.6nm. …”
-
55
-
56
-
57
-
58
-
59
-
60